Dupilumab is safe and effective for treating atopic dermatitis in infants and preschoolers for up to a year.

Published Date: 09 May 2024

Dupilumab (dupixent; Sanofi and Regeneron) showed positive safety and efficacy results for up to 1 year in infants and preschool-aged children with atopic dermatitis, according to new study data presented at the 2024 Pediatric Academic Societies Meeting.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Next Day Mood Is Affected by Ability to Recover From Work.

2.

Enhanced CAR T cell therapy offers new strategy for lymphoma

3.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

4.

Decrease seen in in situ breast cancer since 2009

5.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot